Lapse of Unlisted Options
Released
Released
Announcement PDF
ASX Announcement
2 March 2020
ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
Sydney NSW 2000
Lapse of Unlisted Options
Melbourne, Australia, 2 March 2020 – The Board of Directors of Avecho Biotechnology Limited (ASX:
AVE), an Australian drug delivery company, advises that the following options have lapsed.
ASX Code
AVEAS
AVEAS
AVEAS
AVEAS
Number of options
3,000,000 Options issued on 23 May 2014, expired on 22 May 2019
33,948,150 2016 Options issued on 6 October 2016, expiring 10 September 2021
15,000,000 2016 Options issued on 5 June 2017, expiring 10 September 2021
1,500,000 2016 Options issued on 5 June 2017, expiring 10 September 2021
The Company’s current capital structure therefore constitutes of the following securities:
ASX Code
AVE
AVEAS
Total number of securities and description
1,577,457,420 Fully Paid Ordinary Shares
3,750,000 2017 Options issued on 5 June 2017, expiring 10 September 2021
For enquiries, please contact
Melanie Leydin
Company Secretary
+61 3 9692 7222
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited (ASX:AVE) develops and commercialises innovative Human Health, Animal
Health and Personal Care products using its proprietary drug delivery system called TPM ® (Targeted
Penetration Matrix). TPM® is derived from Vitamin E using unique, proprietary and patented processes and
is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.
Avecho’s major projects include delivering TPM® enhanced patches, gels and injectable products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
Avecho Biotechnology Limited | ASX:AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Share your feedback
Discover